

STUDENT MEDICAL REPORT

For Graduate and Part-time Undergraduate Students

The State of Connecticut General Statutes Section 10a - 155 and Fairfield University require each full-time or matriculating student to provide proof of immunity or screening against measles, mumps, rubella, varicella, meningitis and tuberculosis. Matriculating students are defined as those enrolled in a degree seeking program. This includes both undergraduate and graduate students.

The following are MANDATORY:

Proof of immunity to Measles, Mumps and Rubella (MMR) (Students born before Jan. 1, 1957 are exempt)—You must provide proof of one of the following:

Two MMR immunizations (one on or after your first birthday and after Jan. 1, 1969 AND one at least 28 days later and after Jan. 1, 1980)*, OR

Documentation of positive MMR titer (blood test), OR

Documentation of date of MMR disease by your health care provider

Proof of immunity to Varicella (Chickenpox) (Students born in the U.S.A. before Jan. 1, 1980 are exempt)—You must provide proof of one of the following:

Two varicella immunizations (one on or after your first birthday and one at least 28 days later)*, OR

Documentation of positive Varicella titer (blood test), OR

Documentation of date of varicella disease by your health care provider

*** HealthCare Providers please note: The recommended minimum interval between doses of two live injectable vaccines is 28 days if the doses are not given simultaneously.**

Proof of Immunity to Meningitis (Required for students living on campus only)—You must provide proof of having received a quadrivalent meningococcal conjugate vaccine not more than five (5) years before enrollment. Examples of quadrivalent meningococcal conjugate vaccine include *Menactra*® or *Menveo*®.

Tuberculosis (TB) Screening ALL students are required to complete a series of TB risk assessment questions. Students determined to be at high risk for TB need TB testing as outlined on the Medical Report Form.

Hepatitis B immunization is recommended. (This is not a requirement.) A Hepatitis B Fact Sheet is available on the Student Health Center web page.

Serogroup B Meningococcal Vaccine is recommended. (This is not a requirement.) Teens and young adults (16 through 23 year olds) **may** also be vaccinated with a serogroup B meningococcal vaccine (*Bexsero*® or *Trumenba*®) to provide protection against most strains of serogroup B meningococcal disease. Two or three doses are needed depending on the brand.

IT IS MANDATORY THAT YOU DOCUMENT THE REQUIREMENTS USING THE STUDENT MEDICAL REPORT FORM (see below) BEFORE YOU MAY REGISTER FOR CLASSES AT FAIRFIELD UNIVERSITY.

IMMUNIZATION EXEMPTIONS:

Students born prior to January 1, 1957 are exempted by age to the measles, mumps and rubella requirement.

Students **born in the U.S.A.** before January 1, 1980 are exempted by age to the varicella requirement.

The university will only permit vaccination waivers for religious or medical reasons. A signed Immunization Exemption Form indicating the specific medical contraindication from your health care provide is required for medical exemption. A signed Immunization Exemption Form stating religious objections to immunization must be submitted in order to obtain a religious exemption. The Immunization Exemption Form is available on the Student Health Center web page.

Exemption for either medical or religious reasons subjects the individual to exclusion from campus in the event of an outbreak of a disease for which immunizations are required.

Mandatory immunization requirements are strictly enforced. Please consult your private health care provider to obtain necessary vaccinations. The Student Health Center is not able to offer all vaccinations.

Please Note: Students enrolled in the Fairfield University School of Nursing will be notified of additional specialized immunization requirements and documentation procedures.



This form is to be used by the following student groups (Please indicate your group or program):

- Graduate Student, Degree Seeking Part-time Undergraduate Student, RN to BSN Program, Second Degree Nursing Program

This medical report in its entirety is to be mailed to: Student Health Center, Dolan Hall, Fairfield University, 1073 North Benson Road, Fairfield, CT 06824-5195 (Please keep a copy for your personal records)

This page to be completed by the student (required). ID

Name Gender Date of Birth

Address # Street Home Phone No.

City State Zip Cell Phone No.

E-mail Address

Emergency Contact Home Phone Cell Phone Relationship to you

School you are enrolling in:

- Charles F. Dolan School of Business, College of Arts and Sciences, Graduate School of Education and Allied Professions, School of Engineering, School of Nursing, (Includes Second Degree Nursing Program and RN to BSN Program)

INSTRUCTIONS:

The student and his/her Health Care Provider should complete this Medical Report as directed. All forms must be completed in English. Dates should be listed as Month/Date/Year. Completed forms should be mailed to the Student Health Center at the above address. Please keep a copy of the completed form for your personal records.

All information contained on this form is privileged and confidential and may not be copied or distributed without the permission of the student.

The following questions are required to determine if any immunization/immunity exemptions apply:

Your date of birth is

Will you be living in on-campus or University owned housing? YES NO

Were you born in the United States of America? YES NO

If NO, please list country of birth

Is your undergraduate degree from Fairfield University? YES NO

This page to be completed by your Healthcare Provider.

MMR (Measles, Mumps and Rubella) Immunizations/Immunity (required by state law for students born 1/1/57 or after):

MMR Vaccine Date#1 ____/____/____ MMR Vaccine Date#2 ____/____/____

OR attach copy of MMR titer results OR attach certificate of disease from a physician

Varicella (Chickenpox) Immunizations/Immunity (required by state law. Students born in the USA before 1/1/80 are exempt from this requirement):

Vaccine Date#1 ____/____/____ Vaccine Date#2 ____/____/____

OR attach copy of Varicella titer results OR Date of disease ____/____/____

Quadrivalent Meningococcal Immunization (required by state law for students living on campus only): Must be within the 5 years prior to starting classes, (minimum 1 dose required):

Vaccine Date #1 ____/____/____ Vaccine Date #2 ____/____/____

Recommended Immunizations (not required):

Tetanus Vaccine Date ____/____/____ Td Tdap Updated within 10 years

Hepatitis B Series Date#1 ____/____/____ Date#2 ____/____/____ Date#3 ____/____/____

Serogroup B Meningococcal Vaccine (students ages 16-23)		Recommended, not required	
<i>Bexsero</i> [®]	OR	<i>Trumenba</i> [®]	
Date#1 ____/____/____ #2 ____/____/____		Date#1 ____/____/____ #2 ____/____/____ #3 ____/____/____	

Tuberculosis (TB) Screening (required):

PART I: To be completed by student and reviewed by health care provider:

Have you ever had a positive tuberculosis skin or blood test in the past? Yes No

Have you ever had close contact with persons known or suspected to have active TB disease? Yes No

Were you born in a country that has a high incidence of active TB disease (see Appendix A, page 4)? Yes No

Have you had frequent or prolonged visits* to one or more of the countries listed in Appendix A? Yes No

Have you been a resident, employee, or volunteer in a high risk congregate setting (e.g. correctional facilities, homeless shelters, high risk health care facilities)? Yes No

Do you have a health condition (listed in Appendix B) which suppresses your immune system? Yes No

If the answer is YES to any of the above questions, TB testing (as outlined in Part II) is required. Continue to Part II.

If the answer is **NO** to all of the above questions no further testing or action is required. You may stop here.

Signature of Health Care Provider _____

Date _____

Print Name _____

Address _____

Phone No. _____

*The significance of the exposure should be discussed with a health care provider and evaluated.

Reviewed by SHC RN: Initials ____ Date ____

Part II Tuberculosis (TB) Screening:

Clinical Assessment by the Health Care Provider: Clinicians should review and verify the information in Part I. Only persons answering YES to any of the questions in Part I are candidates for either Mantoux Tuberculin Skin Test or Interferon Gamma Release Assay (IGRA), (unless a previous positive test has been documented).

Does this student have a history of positive TB skin test or IGRA blood test? Yes No

(If YES, document below)

Does this student have a history of BCG vaccination? (If yes, consider IGRA, if possible) Yes No

(A history of BCG vaccination does not preclude testing of a member of a high risk group.)

1. Does the student have signs and symptoms of active tuberculosis disease? Yes No

If NO (and student is high risk for TB), proceed to #2 or #3.

If YES, proceed with evaluation to exclude active TB disease including TST, chest X-ray and sputum evaluation as indicated.

2. Tuberculin Skin Test (TST)

TST result should be recorded in mm of induration, transverse diameter, if no induration, write "0".

See Appendix C for interpretation guidelines.

Date given: ____/____/____

Date read: ____/____/____

Result ____ mm induration

Interpretation: Positive

Negative

3. Interferon Gamma Release Assay (IGRA)

Date obtained: ____/____/____

Result: Positive

Negative

4. Chest X-Ray (Required if TST or IGRA is positive):

Date of Chest X-Ray: ____/____/____

Results: Normal

Abnormal

(Report to Health Dept. if abnormal chest X-Ray)

PART III Management of Positive TST or IGRA

All students with a positive TST or IGRA with no signs of active disease on chest X-Ray should receive a recommendation to be treated for latent TB with appropriate medication.

Student agrees to receive treatment.

Student declines treatment at this time.

This student has completed TB treatment List medication(s) and dates of treatment:

Medication(s): _____ Dates of treatment: _____

Signature of Health Care Provider

Date

Print Name

Address

Phone No.

Appendix A: List of high¹ risk TB countries. Circle country or countries identified in part I of TB screening:

Afghanistan	China, Hong Kong SAR	Haiti	Myanmar	South Africa
Albania	China, Macao SAR	Honduras	Namibia	South Sudan
Algeria	Colombia	India	Nauru	Sri Lanka
Angola	Comoros	Indonesia	Nepal	Sudan
Anguilla	Congo	Iraq	Nicaragua	Suriname
Argentina	Côte d'Ivoire	Kazakhstan	Niger	Swaziland
Armenia	Democratic People's Republic of Korea	Kenya	Nigeria	Tajikistan
Azerbaijan	Democratic Republic of the Congo	Kiribati	Niue	Tanzania (United Republic of)
Bangladesh	Djibouti	Kuwait	Northern Mariana Islands	Thailand
Belarus	Dominican Republic	Kyrgyzstan	Pakistan	Timor-Leste
Belize	Ecuador	Lao People's Democratic Republic	Palau	Togo
Benin	El Salvador	Latvia	Panama	Tunisia
Bhutan	Equatorial Guinea	Lesotho	Papua New Guinea	Turkmenistan
Bolivia (Plurinational State of)	Eritrea	Liberia	Paraguay	Tuvalu
Bosnia and Herzegovina	Ethiopia	Libya	Peru	Uganda
Botswana	eSwatini	Lithuania	Philippines	Ukraine
Brazil	Fiji	Madagascar	Portugal	Uruguay
Brunei Darussalam	French-Polynesia	Malawi	Qatar	Uzbekistan
Bulgaria	Gabon	Malaysia	Republic of Korea	Vanuatu
Burkina Faso	Gambia	Maldives	Republic of Moldova	Venezuela (Bolivarian Republic of)
Burundi	Georgia	Mali	Romania	Viet Nam
Cabo Verde	Greenland	Marshall Islands	Russian Federation	Yemen
Cambodia	Guam	Mauritania	Rwanda	Zambia
Cameroon	Guatemala	Mexico	Sao Tome and Principe	Zimbabwe
Central African Republic	Guinea	Micronesia (Federated States of)	Senegal	
Chad	Guinea-Bissau	Mongolia	Sierra Leone	
China	Guyana	Morocco	Singapore	
		Mozambique	Solomon Islands	
			Somalia	

Appendix B: Health Conditions causing immune suppression:

- HIV/AIDS
- Organ Transplant recipient
- Immunosuppressed persons:
e.g. taking > 15mg/day of prednisone for >1 month; immunosuppressive therapy (TNF- α antagonist, cancer chemotherapy)

Appendix C: TST Interpretation Guidelines:**>5 mm is positive:**

- Recent close contacts of an individual with infectious TB
- persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month.)
- HIV-infected persons

>10 mm is positive:

- recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time
- injection drug users
- mycobacteriology laboratory personnel
- residents, employees, or volunteers in high-risk congregate settings
- persons with medical conditions that increase the risk of progression to TB disease including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunioileal bypass and weight loss of at least 10% below ideal body weight.

>15 mm is positive:

- persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.

*The significance of the travel exposure should be discussed with a health care provider and evaluated.

¹ Incidence rate of $\geq 20/100,000$
Data available at: www.who.int/tb/country/data/profiles/en/